Open an account

Evotec SE

EVO · XETRA

$1.50−$0.04 (−2.60%)TodayMarket closed ·
Prev close $1.54

About EVO

Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees
4,526
Headquarters
Hamburg, Hamburg
Listed
Oct 11, 1999
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
evotec.com

EVO key statistics

Market cap
504.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
104.82K
Volume
20.61K
Open price
$1.50
High today
$1.53
Low today
$1.50
52 Week high
$4.27
52 Week low
$1.33

Evotec SE (EVO) at a glance

As of Oct 23, 2026, Evotec SE (EVO) shares are priced at $1.50, giving the company a market cap of 504.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.50 and $1.53. The current price is 0.0% above the day's low and 2.0% below its high.

Volume so far is 20.61K shares, below the average of 104.82K shares a day.

Over the past year Evotec SE has ranged from $1.33 to $4.27, and now sits 6% of the way up that range.

Evotec SE met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of -$0.3838.

The average analyst price target is $2.44, 62.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $2.44
Low
$1.65
Now
$1.50
High
$5.73

EVO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 32.3% on average.

  1. Q2 FY24: reported -$0.54 per share against an estimate of -$0.1044
  2. Q3 FY24: reported -$0.22 per share against an estimate of -$0.1077
  3. Q4 FY24: reported -$0.23 per share against an estimate of $0.0101
  4. Q2 FY25: reported -$0.24 per share against an estimate of -$0.197
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.1162
  6. Q4 FY25: reported $0.08 per share against an estimate of $0.3131
  7. Q1 FY26: reported -$0.69 per share against an estimate of -$0.303
  8. Q2 FY26: reported -$0.26 per share against an estimate of -$0.3838

EVO news

  • Press releasePRNewswire

    Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

  • Avi Kapoor

    Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

  • Press releasePRNewswire

    Evotec Announces Chief Scientific Officer Transition

  • Press releasePRNewswire

    Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies

  • Press releasePRNewswire

    Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

  • Press releasePRNewswire

    Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

  • Press releaseBusiness Wire

    Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

  • Press releaseBusiness Wire

    Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.